Boehringer Ingelheim has opened another front in its attack on chronic kidney disease (CKD), offering Rectify Pharmaceuticals up to $448 million to partner on a preclinical program.

Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for ...

A new study led by scientists at the Perception Dynamics Institute and the University of California San Diego demonstrates ...

As the global population ages, 2025 has delivered a remarkable wave of new research aimed at supporting healthier brains in ...

Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2 -- Affecting up to 100,000 people in the U.S. and up to 5.6 ...

ESET researchers provide a comprehensive analysis and assessment of a critical severity vulnerability with low likelihood of ...

The program, included in President Donald Trump’s “Big Beautiful Bill,” offers a generous tax incentive to people who donate to scholarship organizations.

Physical inactivity and sedentary behavior are growing worldwide among children and can negatively impact both their physical ...

Another driver arrested in one of last week’s RIDE programs was charged with impaired driving at a holiday season spot check ...

Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in combination with GLP-1 RA -- -- Incremental weight loss is an accep ...

The recent grants, totaling $572,600, will fund research projects in fields ranging from biology to artificial intelligence.